559 related articles for article (PubMed ID: 32729887)
1. Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
Geuzinge HA; Obdeijn IM; Rutgers EJT; Saadatmand S; Mann RM; Oosterwijk JC; Tollenaar RAEM; de Roy van Zuidewijn DBW; Lobbes MBI; van 't Riet M; Hooning MJ; Ausems MGEM; Loo CE; Wesseling J; Luiten EJT; Zonderland HM; Verhoef C; Heijnsdijk EAM; Tilanus-Linthorst MMA; de Koning HJ;
JAMA Oncol; 2020 Sep; 6(9):1381-1389. PubMed ID: 32729887
[TBL] [Abstract][Full Text] [Related]
2. Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
Phi XA; Greuter MJW; Obdeijn IM; Oosterwijk JC; Feenstra TL; Houssami N; de Bock GH
Breast; 2019 Jun; 45():82-88. PubMed ID: 30904701
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ
J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer.
Griebsch I; Brown J; Boggis C; Dixon A; Dixon M; Easton D; Eeles R; Evans DG; Gilbert FJ; Hawnaur J; Kessar P; Lakhani SR; Moss SM; Nerurkar A; Padhani AR; Pointon LJ; Potterton J; Thompson D; Turnbull LW; Walker LG; Warren R; Leach MO;
Br J Cancer; 2006 Oct; 95(7):801-10. PubMed ID: 17016484
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers.
Cott Chubiz JE; Lee JM; Gilmore ME; Kong CY; Lowry KP; Halpern EF; McMahon PM; Ryan PD; Gazelle GS
Cancer; 2013 Mar; 119(6):1266-76. PubMed ID: 23184400
[TBL] [Abstract][Full Text] [Related]
6. MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.
Saadatmand S; Geuzinge HA; Rutgers EJT; Mann RM; de Roy van Zuidewijn DBW; Zonderland HM; Tollenaar RAEM; Lobbes MBI; Ausems MGEM; van 't Riet M; Hooning MJ; Mares-Engelberts I; Luiten EJT; Heijnsdijk EAM; Verhoef C; Karssemeijer N; Oosterwijk JC; Obdeijn IM; de Koning HJ; Tilanus-Linthorst MMA;
Lancet Oncol; 2019 Aug; 20(8):1136-1147. PubMed ID: 31221620
[TBL] [Abstract][Full Text] [Related]
7. Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness.
de Bock GH; Vermeulen KM; Jansen L; Oosterwijk JC; Siesling S; Dorrius MD; Feenstra T; Houssami N; Greuter MJ
Br J Cancer; 2013 Apr; 108(8):1579-86. PubMed ID: 23579217
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.
Pataky R; Armstrong L; Chia S; Coldman AJ; Kim-Sing C; McGillivray B; Scott J; Wilson CM; Peacock S
BMC Cancer; 2013 Jul; 13():339. PubMed ID: 23837641
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
Plevritis SK; Kurian AW; Sigal BM; Daniel BL; Ikeda DM; Stockdale FE; Garber AM
JAMA; 2006 May; 295(20):2374-84. PubMed ID: 16720823
[TBL] [Abstract][Full Text] [Related]
11. Cancer screening with digital mammography for women at average risk for breast cancer, magnetic resonance imaging (MRI) for women at high risk: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(3):1-55. PubMed ID: 23074406
[TBL] [Abstract][Full Text] [Related]
12. Clinical Benefits, Harms, and Cost-Effectiveness of Breast Cancer Screening for Survivors of Childhood Cancer Treated With Chest Radiation : A Comparative Modeling Study.
Yeh JM; Lowry KP; Schechter CB; Diller LR; Alagoz O; Armstrong GT; Hampton JM; Leisenring W; Liu Q; Mandelblatt JS; Miglioretti DL; Moskowitz CS; Oeffinger KC; Trentham-Dietz A; Stout NK
Ann Intern Med; 2020 Sep; 173(5):331-341. PubMed ID: 32628531
[TBL] [Abstract][Full Text] [Related]
13. Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness.
Schousboe JT; Kerlikowske K; Loh A; Cummings SR
Ann Intern Med; 2011 Jul; 155(1):10-20. PubMed ID: 21727289
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Magnetic Resonance Imaging Screening for Women With Extremely Dense Breast Tissue.
Geuzinge HA; Bakker MF; Heijnsdijk EAM; van Ravesteyn NT; Veldhuis WB; Pijnappel RM; de Lange SV; Emaus MJ; Mann RM; Monninkhof EM; de Koekkoek-Doll PK; van Gils CH; de Koning HJ;
J Natl Cancer Inst; 2021 Nov; 113(11):1476-1483. PubMed ID: 34585249
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
Manchanda R; Legood R; Burnell M; McGuire A; Raikou M; Loggenberg K; Wardle J; Sanderson S; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
J Natl Cancer Inst; 2015 Jan; 107(1):380. PubMed ID: 25435542
[TBL] [Abstract][Full Text] [Related]
16. Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial.
Saadatmand S; Rutgers EJ; Tollenaar RA; Zonderland HM; Ausems MG; Keymeulen KB; Schlooz-Vries MS; Koppert LB; Heijnsdijk EA; Seynaeve C; Verhoef C; Oosterwijk JC; Obdeijn IM; de Koning HJ; Tilanus-Linthorst MM
BMC Cancer; 2012 Oct; 12():440. PubMed ID: 23031619
[TBL] [Abstract][Full Text] [Related]
17. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
Gamble C; Havrilesky LJ; Myers ER; Chino JP; Hollenbeck S; Plichta JK; Kelly Marcom P; Shelley Hwang E; Kauff ND; Greenup RA
Ann Surg Oncol; 2017 Oct; 24(11):3116-3123. PubMed ID: 28699130
[TBL] [Abstract][Full Text] [Related]
18. A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.
Li Y; Arellano AR; Bare LA; Bender RA; Strom CM; Devlin JJ
Value Health; 2017 Apr; 20(4):547-555. PubMed ID: 28407996
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population.
Moore SG; Shenoy PJ; Fanucchi L; Tumeh JW; Flowers CR
BMC Health Serv Res; 2009 Jan; 9():9. PubMed ID: 19144138
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers.
Lee JM; McMahon PM; Kong CY; Kopans DB; Ryan PD; Ozanne EM; Halpern EF; Gazelle GS
Radiology; 2010 Mar; 254(3):793-800. PubMed ID: 20177093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
